Address: Medawar Centre, Robert Robinson Avenue, The Oxford Science Park, Oxford, OX4 4GA,United Kingdom
Tel: +44 (0) 1865 783 000
Web: http://www.oxfordbiomedica.co.uk/
Oxford BioMedica has established a platform of technologies in gene delivery and immunotherapy, protected by an extensive intellectual property estate. Through in-house and collaborative development, the Company has a broad pipeline of gene-based product candidates for the treatment of age-related or inherited neurodegenerative and ocular diseases. In addition, Oxford BioMedica and its collaborators are developing novel targeted therapies and therapeutic vaccines to treat multiple types of cancer.
Oxford BioMedica’s two lead programmes are a gene therapy for Parkinson’s disease (ProSavin®) in Phase I/II development and a therapeutic cancer vaccine (TroVax®) in Phase II development.
The other products include RetinoStat®, StarGen™, UshStat™, EncorStat™, MoNuDin®, Hi-8® MEL, MetXia®, EndoAngio-GT and Targeted Antibody Therapy.
The latest news from UK healthcare and life sciences, including the safety review of Novo Nordisk’s GLP-1 receptor agonists; VaxEquity’s grant to scale up RNA vaccine manufacturing; AstraZeneca/Quell Therapeutics cell…
Life sciences have been steadily losing ground in the UK with a significant drop in global R&D investments and a decreasing number of patients enrolled in clinical trials. The British…
Several macro-trends affected the pharmaceutical industry in 2022, impacting its inventory position, writes Matthew Bardell, managing director of specialist inventory consultants nVentic. Bardell highlights findings in a recent report –…
The latest news from UK healthcare and the life sciences, including a record rise in the number of people using private healthcare services due to significant strains on the National…
Airfinity’s Dr Patricia Gallego highlights the persistent threat that COVID-19 continues to present to patients and healthcare systems around the world and outlines the urgent need for more vaccine breakthroughs…
The UK government has decided to go ahead with a much-debated increase in the revenue clawback rate —from 24.4 percent to 27.5 percent— for drugmakers subject to its Statutory Scheme…
Dr Matt Linley, senior director for analytics and forecasting at predictive health analytics firm Airfinity, looks ahead to a potentially game-changing year in the fight against respiratory synctial virus (RSV),…
A roundup of the latest UK healthcare, pharma and biotech news including AbbVie and Lilly’s departure from the country’s voluntary medicines pricing agreement, Moderna’s expanded footprint, UK biotech’s 2022 funding…
What digital skills do pharma leaders need in order to drive transformation, deliver success at scale in the business, and prepare for next-gen customer engagement? Sarah Gilchriest explores the critical…
Bernard Ross, a serial entrepreneur with more than 20 years’ senior experience at private and public board level across multiple industries, looks ahead to 2023 and highlights five key trends…
After an almost 20-year career in Big Pharma culminating in a role as president of AstraZeneca UK, Lisa Anson took the leap into the biotech world to lead what at…
Pricing and market access have become increasingly hot topics in recent years, as healthcare systems across the world attempt to balance their own financial sustainability with securing the latest medical…
See our Cookie Privacy Policy Here